Stock Research Report for Solara Active Pharma Sciences Ltd

Stock score of Solara Active Pharma Sciences Ltd moved up by 1 in a week on a 10 point scale (Source: Refinitiv). Get detailed report on Solara Active Pharma Sciences Ltd by subscribing to ETPrime.

Stock Reports Plus

Get 4000+ Stock Reports worth₹ 1,499* with ETPrimeat no extra cost for you

*As per competitive benchmarking of annual price. T&C apply

FEATURES & BENEFITS
What you get with Stock Reports Plus?
  • Make Investment decisions

    with proprietary stock scores on earnings, fundamentals, relative valuation, risk and price momentum

  • Find new Trading ideas

    with weekly updated scores and analysts forecasts on key data points

  • In-Depth analysis

    of company and its peers through independent research, ratings, and market data

Login to View Sample Report
Sandeep, now enjoy Stock Reports Plus worth ₹ 1,499*
offered complimentary with your ETPrime membership

*As per competitive benchmarking of annual price. T&C apply

About SOLARA

Solara Active Pharma Sciences Limited is an India-based company offering diversified, commercial active pharmaceutical ingredients (APIs) and contract manufacturing services in over 70 countries. The Company operates through the API segment. Its commercial and research and development products include Albendazole, Aprepitant (Antiemetic), Artesunate, Brivaracetam (Antiepileptic), Bumetanide (Inj) (Loop Diuretic), Buspirone HCL (Anxiolytic), Cetirizine Dihydrochloride, Chlorpromazine Hydrochloride, Cinacalcet Hydrochloride (Calcimimetic Agent), Citicoline Sodium (Anticonvulsant), Colchicine (Antigout Agent), Colesevelam Hydrochloride, Cycloserine (Antitubercular), Ethacrynic Acid (Cardiovascular Agent), Hydralazine Hydrochloride (Anti-Hypertensive), Ibuprofen Sodium Dihydrate (Anti-inflammatory), Mesna (Antineoplastic Detoxifying Agent), Mirabegron (OAB Treatment), Pentoxifylline, and others. The Company works with pharmaceutical companies from North America, Europe, and Japan.

Frequently Asked Questions
The Economic Times